Ceftriaxone Sodium (1gram) Powder for Injection
|FOB Price:||US $0.25 / carton|
|Min. Order:||1,000 carton|
|Min. Order||FOB Price|
|1,000 carton||US $0.25/ carton|
|Production Capacity:||50000 Vial /Month|
|Payment Terms:||L/C, T/T, Western Union, Paypal, Money Gram|
- Model NO.: powder for injection
- Usage Mode: Injection
- State: Powder
- Type: Organic Chemicals
- Dosage: 1g/Vial for 10ml
- Classify: Antibiotic
- Transport Package: Box
- Origin: China
- Application: I.M/I.V
- Suitable for: Adult
- Shape: Powder
- Pharmaceutical Technology: Chemical Synthesis
- Use: for Injection
- Trademark: sunbiolab
- Specification: 1G/1.5G/2G
Antibiotic Ceftriaxone Sodium Injection For Bacterial Infection
Ceftriaxone, sold under the trade name Rocephin, is an antibiotic useful for the treatment of a number of bacterial infections. This includes pneumonia, ear infections, skin infections, urinary tract infections, gonorrhea, pelvic inflammatory disease, sepsis, bone and joint infections, intra-abdominal infections, and meningitis. It is also used preoperatively to reduce the risk of postoperative infections. It is administered by intravenous or intramuscular injection.
The most common side effects are related to route of drug administration, including pain at the site of intramuscular injection and thrombophlebitis in intravenous administration. Gastrointestinal upset is also common. Due to precipitation of ceftriaxone in bile, biliary sludging, gallstones, and cholecystitis are also possible, if less common.It should not be used in newborns due to the risks of bilirubin encephalopathy and ceftriaxone-calcium precipitation. Dosage adjustment is usually required in people with kidney failure. Caution should be used in those who have had serious allergic reactions to penicillin.
It is a third-generation cephalosporin. Like other third-generation cephalosporins, it has broad-spectrum activity against Gram-positive bacteria and expanded Gram-negative coverage compared to second-generation agents. In most cases, it is considered to be equivalent to cefotaxime in terms of spectrum of antibacterial activity.
Ceftriaxone sodium is marketed by Hoffmann-La Roche. It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system.
Ceftriaxone and other third-generation antibiotics are used to treat organisms that tend to be resistant to many other antibiotics. Due to emergent resistance, ceftriaxone should not be used for the treatment of Enterobacter infections. Before using ceftriaxone, it is important to determine the susceptibility of the bacteria. If sepsis is being considered, empiric therapy may be initiated prior to susceptibility testing in immunocompromised and Immunocompetent patients.
According to the package insert,clinical indications for ceftriaxone include:
lower respiratory tract infections
acute bacterial otitis media
skin and skin structure infections
urinary tract infections
pelvic inflammatory disease
It is also a choice drug for treatment of bacterial meningitis caused by pneumococci, meningococci, Haemophilus influenzae, and "susceptible enteric Gram-negative rods, but not Listeria monocytogenes."
In combination with doxycycline or azithromycin, ceftriaxone is recommended by the United States Centers for Disease Control for the treatment of gonorrhea. By itself, it is not recommended due to the potential for resistance development.
Ceftriaxone is available for administration via the intramuscular or the intravenous routes.Diluents containing calcium should not be used to reconstitute ceftriaxone and it must not be administered in intravenous lines containing other calcium-containing solutions, as a ceftriaxone-calcium precipitate could form.
Ceftriaxone is pregnancy category B. It has not been observed to cause birth defects in animal studies, but a lack of well-controlled studies done in pregnant women exists.
Low concentrations of ceftriaxone are excreted in breast milk that are "not expected to cause adverse effects in breastfed infants."The manufacturer recommends that caution be exercised when administering ceftriaxone to women who breastfeed.
Hyperbilirubinemic neonates are contraindicated for the use of ceftriaxone.It can compete with bilirubin and displace it from binding to albumin, increasing the risk of bilirubin encephalopathy.
According to the package insert, clinical studies did not show differences in efficacy and safety of ceftriaxone in geriatrics compared to younger patients but "greater sensitivity of some older individuals cannot be ruled out."